KY1044 is currently being evaluated in phase 1/2 trials in selected advanced malignancies (NCT03829501) in combination with anti-PD-L1 (atezolizumab, Roche, Basel, Switzerland) in order to prove the efficacy of a combined Treg reduction and cytotoxic CD8+ T-cell reactivation in cancer immunotherapy. This evidence concerns the gene CD8A and cancer.